STAT3 and esophageal squamous cell carcinoma: In ESCC was shown that MEK inhibitors, targeting the RAS-RAF-MEK-MAPK-ELK1 pathway, activate STAT3-mediated signaling, while dual inhibition of the two pathways resulted in decreased cell proliferation [205].